This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Venlafaxine in the Treatment of Dysthymia: An Open-Label Study

David J. Hellerstein, Sarai T. Batchelder, Suzanne A. S. Little, Michael J. Fedak, David Kreditor, and Jesse Rosenthal

Published: December 31, 1999

Article Abstract

Background: Numerous studies have demonstrated the effectiveness of antidepressant medications in the treatment of dysthymia, or chronic mild depression. Venlafaxine blocks reuptake of both serotonin and norepinephrine and may produce a more complete antidepressant response than do single-mechanism selective serotonin reuptake inhibitors. The purpose of this open-label study was to provide preliminary data on the tolerability and effectiveness of venlafaxine for patients with dysthymia.

Method: Twenty-two dysthymic subjects (DSM-III-R criteria) were enrolled in this 10-week, open-label trial, and 5 dropped out prior to their second visit. Seventeen subjects (77.3%) received more than 1 week of medication.

Results: Of these 17 subjects, 13 (76.5%) were treatment responders. Results of paired sample t tests were highly significant, indicating that, on average, there was significant improvement on all measures of symptomatology and functioning, with mean ± SD scores on the Hamilton Rating Scale for Depression decreasing from 20.95 ± 6.50 at baseline to 6.06 ± 5.49 at week 10. The mean ± SD final dose was 178.68 ± 70.80 mg/day. Side effects were reported by 17 (85%) of the 20 subjects for whom tolerability was assessed (the most common were fatigue, dry mouth, and nausea); 5 (22.7%) of 22 patients discontinued treatment because of side effects, primarily nausea (N = 3).

Conclusion: These findings suggest the benefit of venlafaxine in the treatment of chronic depression and the need for more rigorous studies.

Volume: 60

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF